Table of Contents
- Why the US and EU Don't Use the Same Application
- How We Compared These Three Application Types
- At a Glance: NDA vs. BLA vs. MAA
- NDA (United States)
- BLA (United States)
- MAA (European Union)
- The Real Difference Isn't the Application — It's Where the Line Falls
- How Kivo's RIM Module Supports NDA, BLA, and MAA Submissions
- FAQ
- Sources
What's the difference between an NDA, a BLA, and an MAA? An NDA (New Drug Application) and a BLA (Biologics License Application) are both US FDA filings—NDAs for chemically synthesized drugs under the Food, Drug, and Cosmetic Act, BLAs for biological products under the Public Health Service Act. An MAA (Marketing Authorisation Application) is the EU equivalent, filed with the EMA—but the EU doesn't split applications by product type the way the US does. One MAA pathway covers both small-molecule drugs and biologics.
Why the US and EU Don't Use the Same Application
The US ended up with two separate marketing-application pathways for a reason that has nothing to do with science and everything to do with legislative history—and both pathways trace back to a public-health tragedy rather than a planning decision. In late 1901, children in St. Louis who had been given diphtheria antitoxin made from the blood of a tetanus-infected horse began dying of tetanus; 13 children died before the contamination was traced. That outbreak led directly to the 1902 Biologics Control Act, which gave the federal government its first authority over how biological products were manufactured[10]. New Drug Applications have a separate, later origin: in 1937, a liquid sulfanilamide product dissolved in diethylene glycol—an untested, toxic solvent—killed more than 100 people across 15 states, and those deaths directly hastened passage of the 1938 Food, Drug, and Cosmetic Act[11]. NDAs are governed today by Section 505 of that Act; BLAs by Section 351 of the Public Health Service (PHS) Act[1]. Those two laws, born three decades and two different tragedies apart, were never merged. A molecule's legal pathway in the US still depends on which 20th-century statute Congress happened to be amending when the relevant product category was invented.
The EU took a cleaner path because it built its system almost a century later, after the scientific distinction between "chemical drug" and "biological product" was already well understood. The centralised procedure, introduced by Regulation (EEC) No 2309/93 and now governed by Regulation (EC) No 726/2004, created one Marketing Authorisation Application pathway for human medicines, administered by one agency's one scientific committee—the EMA's Committee for Medicinal Products for Human Use (CHMP)—regardless of whether the product is a small molecule, a monoclonal antibody, a cell therapy, or a vaccine[2]. For our companion piece on how these agencies' review timelines compare once a submission is filed, see FDA, EMA, PMDA & More: Global Drug Approval Timelines Compared.
That's the headline difference to hold onto through the rest of this comparison: the US splits by product type into two applications; the EU doesn't split at all. Everything else—format, review standards, exclusivity math—follows from that one structural choice.
How We Compared These Three Application Types
We compared each application on five dimensions that actually change how a regulatory team plans a filing:
- Legal basis. The specific statute or regulation that creates and governs the application.
- Product scope. What kinds of products the application is actually for.
- Review body. Which agency division or committee evaluates it.
- Dossier format. Whether it follows the ICH Common Technical Document (CTD) structure, and how.
- Exclusivity. How long a competing generic or biosimilar is kept off the market after approval—often the single biggest commercial question a sponsor asks about any of these three applications.
A scoping note: this comparison covers original marketing applications for new products, and on the EU side, specifically the centralised procedure. It doesn't cover abbreviated pathways built on top of these three—the ANDA (generic equivalent of an NDA)—or the EU's national, mutual-recognition, and decentralised procedures, which exist for products outside the EMA's mandatory centralised-procedure list (generally reserved for new active substances, orphan drugs, and biotechnology-derived products) and route through individual member-state agencies instead of the EMA directly. Those pathways are different enough, and numerous enough, to deserve their own comparison.
Why this framing matters for a sponsor rather than just a regulatory-affairs trivia question: a molecule's eventual application type is rarely ambiguous by the time a team is actually filing, but it's genuinely uncertain earlier, during late-stage development, for product classes that straddle the line—a chemically synthesized peptide, for instance, or a product combining a small-molecule drug with a biological delivery mechanism. Because exclusivity length differs so substantially between pathways (more on that below), that early classification question carries real commercial weight, not just a paperwork decision about which form to file.
At a Glance: NDA vs. BLA vs. MAA
The NDA and BLA share a statute family, a review-fee structure, and a dossier format; the MAA shares only the dossier format with either one. This table lines up all five comparison dimensions side by side.
| Dimension | NDA (US) | BLA (US) | MAA (EU, centralised procedure) |
|---|---|---|---|
| Legal basis | Section 505, FD&C Act[1] | Section 351, PHS Act[1] | Regulation (EC) No 726/2004[2] |
| Product scope | Chemically synthesized ("small molecule") drugs[3] | Biological products: proteins, vaccines, blood products, gene/cell therapies[3] | All human medicines—small molecules and biologics alike[2] |
| Review body | CDER, always[3] | Mostly CBER; CDER for most therapeutic proteins, mAbs, and growth factors[3] | EMA's CHMP, one committee for every product type[2] |
| User fee framework | PDUFA[3] | PDUFA (same framework as NDAs)[3] | EMA fee regulation (separate from PDUFA/BsUFA entirely) |
| Dossier format | ICH CTD / eCTD[4] | ICH CTD / eCTD[4] | ICH CTD / eCTD[4] |
| Standard exclusivity (current rules) | 5 years (New Chemical Entity exclusivity)[5] | 12 years (reference product exclusivity)[6] | Up to 11 years (8+2+1 data/market protection)[7] |
Two things stand out immediately. First, an NDA and a BLA share the same user-fee framework (PDUFA) and the same dossier format (CTD)—the split is about what the product is, not how either application is built or funded. Second, the exclusivity gap is large: a biologic approved today carries more than double the regulatory exclusivity of a small-molecule drug approved the same day, a gap large enough that it shapes which pathway a company's own product development strategy aims for when a molecule could plausibly go either way.
NDA (United States)
What It Covers & Legal Basis
A New Drug Application is the US marketing-application pathway for chemically synthesized drugs—what the FDA and industry commonly call "small molecule" products—governed by Section 505 of the Food, Drug, and Cosmetic Act[1]. Every NDA, regardless of the specific drug class, is reviewed by the Center for Drug Evaluation and Research (CDER)[3]. For a detailed walkthrough of what goes into building one, see Kivo's own NDA Application Guide.
Format & Review Standard
NDAs are built and submitted in the ICH Common Technical Document format, organized into the now-familiar five-module structure, filed electronically as an eCTD sequence[4]. Review timing runs on the same PDUFA goal structure that governs BLAs—10 months from the application's 60-day filing date for a standard review, 6 months for priority review.
Exclusivity
A genuinely new active moiety approved via NDA earns New Chemical Entity (NCE) exclusivity: 5 years, during which the FDA cannot accept a generic ANDA referencing that product[5]. Additional, narrower exclusivity periods (3-year new-indication exclusivity, pediatric exclusivity, orphan drug exclusivity) can stack on top of NCE exclusivity depending on the specific submission, but 5 years is the baseline most sponsors plan around.
What Sponsors Should Know
Because every NDA goes to CDER and uses the same CTD format as a BLA, a regulatory team rarely struggles with "where does this go"—ambiguity shows up at the product-classification stage, long before the NDA-vs-BLA choice is even live. The harder planning question is exclusivity-driven: because NCE exclusivity (5 years) is less than half of reference product exclusivity (12 years), a molecule that could plausibly be developed as either a small-molecule drug or a biologic carries a real commercial incentive toward the biologic pathway, independent of which one is scientifically more appropriate for the mechanism of action.
BLA (United States)
What It Covers & Legal Basis
A Biologics License Application is the US pathway for biological products—a term defined under Section 351 of the Public Health Service Act to include proteins, vaccines, blood and blood components, allergenic products, and gene and cell therapies[1]. Most BLAs go to the Center for Biologics Evaluation and Research (CBER), but a meaningful subset routes to CDER instead: in vivo monoclonal antibodies, most therapeutic proteins (cytokines, enzymes, novel engineered proteins), immunomodulators, and growth factors[3]. Vaccines and blood products stay with CBER regardless. For the full walkthrough, see Kivo's Biologics License Application (BLA) Guide.
A Real Historical Wrinkle: the 2020 NDA-to-BLA Transition
The line between "small molecule drug" and "biological product" hasn't always been stable, and one specific event shows exactly how much that line matters. The BPCI Act of 2009 amended the PHS Act's definition of "biological product" to include proteins—with a decade-long transition period before the change took effect. On March 23, 2020, that transition period ended: every approved NDA for a product that met the new biological-product definition was automatically deemed an approved BLA under Section 351 of the PHS Act[8]. The FDA's own page on the provision describes the affected category as protein products that had historically been approved under NDAs—insulin and insulin analogs, human growth hormone, pancreatic enzymes, and reproductive hormones among them[8]. Products already on the market didn't change manufacturing or formulation overnight; their legal classification changed, and with it, the exclusivity and biosimilar-competition rules that now applied to them.
Exclusivity
A BLA for a genuinely new biological product earns 12 years of reference product exclusivity under Section 351(k)(7) of the PHS Act, counted from the date of first licensure—more than double an NDA's 5-year NCE exclusivity[6]. A separate, shorter 4-year period within that same 12 years specifically blocks a biosimilar applicant from even submitting an application that relies on the reference product's data, before the fuller approval-blocking effect of the full 12-year period applies.
What Sponsors Should Know
The 2020 transition is worth knowing even for teams with no legacy products affected by it, because it's a clean illustration of a risk that still exists today: a product's classification as "drug" or "biologic" is a legal determination under an evolving statutory definition, not a fixed scientific fact, and that determination can change the exclusivity math on an approved product retroactively. A regulatory information management system that tracks application type as a static field set once at filing will miss that this classification is itself a compliance fact worth monitoring over a product's lifecycle, not just at submission.
MAA (European Union)
What It Covers & Legal Basis
A Marketing Authorisation Application is the EU's pathway to a centralised marketing authorisation, valid across all EU member states (plus Iceland, Liechtenstein, and Norway) at once, governed by Regulation (EC) No 726/2004[2]. Critically, the MAA is not split by product type the way the US splits NDAs from BLAs: one application pathway, reviewed by one scientific committee (the CHMP), covers small-molecule drugs, biologics, advanced-therapy medicinal products, and everything in between[2]. For a side-by-side look at how the US and EU pathways compare more broadly, see Kivo's Guide to Regulatory Submissions in the US (FDA) & EU (EMA); for the MAA process in more depth, see our Marketing Authorisation Application (MAA) Submission Guide.
Format & Review Standard
Like NDAs and BLAs, MAAs are built and submitted in ICH CTD/eCTD format[4]—one of the reasons a global sponsor's dossier structure largely transfers across all three applications, even though the legal frameworks behind them don't. The CHMP's standard review clock runs 210 active days, with a 150-day accelerated-assessment option for products of major public health interest; see Kivo's companion comparison, FDA, EMA, PMDA & More: Global Drug Approval Timelines Compared, for how that measures up against the FDA's own PDUFA goals.
Exclusivity — and a Live 2026 Change in Progress
Under the EU's long-standing rules, a centralised MAA earns 8 years of data exclusivity, followed by 2 years of market protection, with a possible additional 1 year if the product gains an approved new indication offering significant clinical benefit—commonly described as the "8+2+1" model, for a maximum of roughly 11 years[7]. That baseline is in the process of changing: as part of the EU's broader 2026 pharmaceutical legislation reform, trilogue negotiators reached political agreement to cut the standard market-protection period from 2 years to 1 year, replacing "8+2(+1)" with a new "8+1(+1+1)" structure in which the second and third extension years must be earned—through measures such as addressing an unmet medical need, running a head-to-head comparative trial, or (for smaller companies) holding no more than five centralised authorisations—rather than granted automatically[9]. As of this writing, that reform had reached political agreement but had not yet completed the EU's formal adoption process (Parliament and Council sign-off, followed by Official Journal publication), so the 8+2+1 figures in the comparison table above remain the operative rules; sponsors tracking a near-term MAA filing should confirm the reform's adoption status before relying on either figure for long-range planning.
What Sponsors Should Know
The EU's single-pathway model means a regulatory team never has to make the NDA-vs-BLA classification call that matters so much in the US—but it also means the exclusivity math is more fluid right now than the US's. A sponsor whose EU filing timeline straddles the reform's eventual entry into force needs a regulatory information system that can flag exactly which rule set applies to a given submission, rather than assuming today's 8+2+1 figures will still be accurate a year or two out.
Not the Only EU Route — Just the One Comparable to NDA and BLA
The centralised procedure covered here is mandatory for new active substances treating cancer, diabetes, neurodegenerative disease, autoimmune and viral disease, and for orphan drugs and most biotechnology-derived products—in practice, the categories most comparable to a typical NDA or BLA filing. Products outside that mandatory list can instead go through national authorisation in a single member state, or a mutual-recognition or decentralised procedure that extends a national approval (or a simultaneous multi-country application) across several member states without going through the EMA at all. Those routes use different timelines and different authorities than the CHMP-run centralised procedure, which is why this comparison scopes specifically to the centralised MAA—the EU route that actually competes head-to-head with an NDA or BLA for a new, centrally significant product.
The Real Difference Isn't the Application — It's Where the Line Falls
Lay all three applications side by side and the comparison resolves into a single underlying fact: the US draws a hard legal line between "chemical drug" and "biological product" that determines which of two statutes, which of two FDA centers, and which of two exclusivity regimes applies—while the EU draws no such line at all for marketing authorisation. That's not a difference in rigor; the EU's CHMP applies the same CTD-based scientific review to a biologic that it applies to a small molecule, with no biologics-specific sub-pathway comparable to the US's BLA. It's a difference in where regulatory complexity gets absorbed: in the US, it's absorbed upfront, at the point a sponsor decides which application to file; in the EU, it's absorbed inside a single application's own CTD modules, where product-type-specific requirements (Module 3's quality data, in particular) differ substantially between a small molecule and a biologic even though the cover application is identical.
The 2020 NDA-to-BLA transition is the clearest evidence that the US's line isn't static. A statutory definition changed, and products that had been legally classified one way for decades were reclassified overnight, with real exclusivity and competition consequences. The EU's reform now in progress is a parallel reminder from the other side: even a system built around "one pathway for everything" still has rules within that pathway—here, the exclusivity period—that move. For a global sponsor, the practical lesson is the same either way: application type and exclusivity status aren't filed once and forgotten. They're facts a regulatory system needs to keep current against two statutory frameworks and an EU regulation that are each, independently, subject to change.
How Kivo's RIM Module Supports NDA, BLA, and MAA Submissions
Kivo's Regulatory Information Management (RIM) module manages the submission lifecycle, agency correspondence, and commitment tracking across exactly this mix of application types—its submission-type support explicitly includes INDs, CTAs, BLAs, NDAs, IDMPs, ANDAs, and CTIS submissions, built on the EDM (Electronic Document Management) Reference Model. For an EU-bound MAA specifically, RIM's generic submission-building tools—pre-built structures aligned to agency guidelines, a copy-existing-submission function, and automatic export tracking for publishing handoff—apply the same way they do to an NDA or BLA; the eCTD Viewer that sits alongside it accepts eCTD sequences filed through the EMA gateway, the same electronic channel an MAA uses, in addition to the FDA, PMDA, Health Canada, Swissmedic, TGA, HSA, and MFDS gateways.
Because application-type classification can itself change over a product's lifecycle—as the 2020 BLA transition demonstrated—RIM's correspondence and commitment tracking keeps a running, time-stamped record of agency interactions tied to a specific submission, rather than a single static "application type" field set once and never revisited. Kivo doesn't handle eCTD publishing itself; it prepares submission-ready packages with automatic change tracking for handoff to a sponsor's own internal or external publishing group, and keeps every submitted sequence viewable afterward, linked back to its source documents in Kivo's DMS. For more on how Kivo structures the broader submission-management workflow, see RIM Explained: Regulatory Information Management & Systems.
Document control for any of these three applications runs on the same DMS core as Kivo's eTMF and QMS modules—native, Part 11-compliant e-signature included standard with every subscription, at no additional charge, with no separate integration project required to connect submission tracking to the rest of a sponsor's compliance stack. Over 200 sponsor, consultant, and CRO teams currently run on Kivo's platform today.
FAQ
What's the main difference between an NDA and a BLA?
Product type and legal basis. An NDA covers chemically synthesized small-molecule drugs under Section 505 of the FD&C Act; a BLA covers biological products—proteins, vaccines, cell and gene therapies—under Section 351 of the PHS Act. Both use the same CTD dossier format and the same PDUFA user-fee framework.
Why doesn't the EU have separate applications for drugs and biologics?
The EU's centralised procedure was built under Regulation (EC) No 726/2004 as a single pathway for all human medicines, reviewed by one committee (the CHMP) regardless of product type. There's no EU equivalent of the US's BLA-vs-NDA split—product-type differences show up inside the MAA's own dossier modules instead.
Did any drugs actually move from an NDA to a BLA?
Yes. On March 23, 2020, a decade-long statutory transition under the 2009 BPCI Act took effect: every approved NDA for a product meeting the PHS Act's amended biological-product definition—including insulin, human growth hormone, pancreatic enzymes, and certain reproductive hormones—was automatically deemed an approved BLA, with no new data or re-review required.
Is the CTD format the same for NDAs, BLAs, and MAAs?
Yes, all three follow the ICH Common Technical Document structure and are filed electronically as eCTD sequences, which is why a single global dossier largely transfers across all three. What differs is everything underneath that shared format: the governing statute, the review body, the user-fee framework, and the exclusivity rules each application carries.
How might the EU's 2026 pharmaceutical reform change MAA exclusivity?
The reform, still completing formal EU adoption as of this writing, would replace the current "8+2+1" model (8 years data exclusivity, up to 3 more years market protection) with an "8+1(+1+1)" model where the extra years must be earned rather than granted automatically—likely a lower default exclusivity period for most new MAAs.
Sources
- U.S. Food and Drug Administration. "Deemed to be a License" Provision of the BPCI Act — background on the FD&C Act Section 505 / PHS Act Section 351 statutory split.
- European Medicines Agency. Regulation (EC) No 726/2004, laying down Union procedures for the authorisation of medicinal products (centralised procedure).
- Allucent. "What is the Difference Between BLA and NDA?" (review-center and user-fee framework detail).
- International Council for Harmonisation. Common Technical Document (CTD) format, M4 guideline.
- U.S. Food and Drug Administration. "Frequently Asked Questions on Patents and Exclusivity" — New Chemical Entity (NCE) exclusivity, 5 years.
- U.S. Food and Drug Administration. "Background Information on the List of Licensed Biological Products, Reference Product Exclusivity" — Section 351(k)(7) of the PHS Act, 12-year reference product exclusivity.
- Patsnap Synapse. "How Long Is Data Exclusivity for Biologics in the US and EU?" (secondary source for the EU's current "8+2+1" data/market protection figures).
- U.S. Food and Drug Administration. "Deemed to be a License" Provision of the BPCI Act — March 23, 2020 transition date and affected product categories (insulin, human growth hormone, pancreatic enzymes, reproductive hormones).
- Osborne Clarke. "EU Overhauls Pharmaceutical Law: Sweeping 2026 Reform Package" (secondary source for the pending "8+1(+1+1)" exclusivity reform, political agreement reached but formal adoption pending as of publication).
- U.S. Food and Drug Administration. "Science and the Regulation of Biological Products" — 1901 St. Louis diphtheria antitoxin/tetanus contamination and the 1902 Biologics Control Act.
- U.S. Food and Drug Administration. "Sulfanilamide Disaster" — the 1937 Elixir Sulfanilamide deaths and their direct role in the 1938 Food, Drug, and Cosmetic Act's passage.

